Clinical Pediatric Endocrinology最新文献_第4页

Clinical utility of TRAb reduction in predicting remission in pediatric Graves' disease. TRAb降低预测小儿Graves病缓解的临床应用

IF 1

Clinical Pediatric Endocrinology Pub Date : 2026-04-01 Epub Date: 2026-02-05 DOI: 10.1297/cpe.2025-0102

Shintaro Terashita, Mariko Nagamori, Yasuhiro Naiki, Aiko Sugiura, Nagisa Ujita, Kenichi Kashimada, Chihaya Imai

{"title":"Clinical utility of TRAb reduction in predicting remission in pediatric Graves' disease.","authors":"Shintaro Terashita, Mariko Nagamori, Yasuhiro Naiki, Aiko Sugiura, Nagisa Ujita, Kenichi Kashimada, Chihaya Imai","doi":"10.1297/cpe.2025-0102","DOIUrl":"10.1297/cpe.2025-0102","url":null,"abstract":"Hyperthyroidism in childhood impairs quality of life, with Graves' disease (GD) being the predominant cause. Although most cases can be managed with antithyroid drugs (ATD), recurrence remains challenging due to its frequency and unpredictability. Although thyrotropin receptor antibody (TRAb) has been proposed as a potential biomarker for predicting recurrence, the details, including the cut-off value, remain to be elucidated. We retrospectively analyzed 41 children (aged 2-15 yr) with GD and initiated ATD between 2005 and 2024 at two centers. Patients were classified into two groups, remission (n = 8) or non-remission (n = 33) based on the duration of euthyroidism for ≥ 24 mo after ATD discontinuation. TRAb levels were measured at the commencement of the therapy and every 6 mo afterward up to 24 mo. TRAb reduction rates (TRR) were significantly greater in the remission group at 6, 18, and 24 mo after treatment initiation. Among these, the 24-mo ROC analysis of TRR yielded the highest predictive value with an optimal cut-point of 93.2% (sensitivity 81.5%, specificity 85.7%). We concluded that the TRR is a potential marker to predict the remission of pediatric GD. Serial monitoring of TRAb would help to optimize the timing of ATD discontinuation.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"35 2","pages":"161-167"},"PeriodicalIF":1.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13038381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-lasting hypoglycemia through insulin degludec during acute kidney injury after diabetic ketoacidosis: A case report. 糖尿病酮症酸中毒后急性肾损伤，经降糖精胰岛素持续降糖1例。

IF 1

Clinical Pediatric Endocrinology Pub Date : 2026-04-01 Epub Date: 2026-01-15 DOI: 10.1297/cpe.2025-0094

Sayaka Kawashima, Tomohisa Suzuki, Hirohito Shima, Dai Suzuki, Miki Kamimura, Atsuo Kikuchi, Junko Kanno

{"title":"Long-lasting hypoglycemia through insulin degludec during acute kidney injury after diabetic ketoacidosis: A case report.","authors":"Sayaka Kawashima, Tomohisa Suzuki, Hirohito Shima, Dai Suzuki, Miki Kamimura, Atsuo Kikuchi, Junko Kanno","doi":"10.1297/cpe.2025-0094","DOIUrl":"10.1297/cpe.2025-0094","url":null,"abstract":"Diabetic ketoacidosis (DKA) may be complicated by acute kidney injury (AKI). While the pharmacokinetics of insulin degludec were previously suggested to be stable even in chronic kidney disease, its safety profile in acute or dynamic renal dysfunction remains unclear. We herein report a 13-yr-old boy with severe DKA complicated by AKI, who developed prolonged hypoglycemia after switching from continuous intravenous regular insulin to subcutaneous insulin aspart and insulin degludec. Insulin degludec was initiated, although the patient was no longer acidotic, during a period when his serum creatinine level was still rising. The patient repeatedly became hypoglycemic, which required the interruption of basal insulin for 8 d. In retrospect, the decision to initiate long-acting insulin during AKI was made in accordance with standard DKA protocols, without sufficient consideration of the deteriorated clearance of insulin degludec under impaired renal function. This case highlights the need for caution when initiating long-acting insulin analogues in patients with AKI, even in the post-DKA phase. Further studies are needed to elucidate insulin pharmacokinetics during non-steady-state renal impairment.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"35 2","pages":"179-185"},"PeriodicalIF":1.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13038383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eﬃcacy and safety of reduced-dose insulin infusion in pediatric diabetic ketoacidosis: a randomized clinical trial. 小剂量胰岛素输注治疗小儿糖尿病酮症酸中毒的疗效和安全性：一项随机临床试验。

IF 1

Clinical Pediatric Endocrinology Pub Date : 2026-04-01 Epub Date: 2025-12-14 DOI: 10.1297/cpe.2025-0072

Hoda Atwa, Marwa Ali, Ahmed Ibrahim

{"title":"Eﬃcacy and safety of reduced-dose insulin infusion in pediatric diabetic ketoacidosis: a randomized clinical trial.","authors":"Hoda Atwa, Marwa Ali, Ahmed Ibrahim","doi":"10.1297/cpe.2025-0072","DOIUrl":"10.1297/cpe.2025-0072","url":null,"abstract":"Diabetic ketoacidosis (DKA) management in children traditionally employs insulin infusion rates of 0.1 units/kg/h, though emerging evidence suggests lower doses may achieve comparable outcomes with enhanced safety profiles. This study aimed to determine whether reduced-dose insulin therapy (0.05 units/kg/h) demonstrates non-inferiority compared to conventional dosing in pediatric DKA management. We conducted a prospective randomized controlled trial involving 70 children presenting with DKA at our pediatric intensive care unit between January and December 2018. Participants were randomly assigned to receive either reduced-dose insulin infusion (0.05 units/kg/h, n = 35) or standard-dose therapy (0.1 units/kg/h, n = 35). Both treatment approaches demonstrated comparable efficacy in achieving metabolic correction. Time to acidosis resolution showed no significant difference between reduced-dose and standard-dose groups (10.2 ± 5.29 vs. 11.22 ± 5.04 h, p = 0.407). However, the reduced-dose protocol exhibited superior safety characteristics, with significantly lower hypokalemia incidence (20.0% vs. 42.9%, p = 0.039) and reduced hypoglycemia rates (11.4% vs. 25.7%). Total insulin consumption was 50% lower in the reduced-dose group. In conclusion, reduced-dose insulin therapy demonstrates non-inferiority to conventional dosing while providing enhanced safety benefits, supporting consideration of lower insulin dosing strategies, particularly in resource-limited settings.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"35 2","pages":"140-151"},"PeriodicalIF":1.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13038384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Growth hormone therapy in a patient with short stature due to fetal alcohol syndrome: seven-year follow-up. 胎儿酒精综合征致身材矮小患者的生长激素治疗：7年随访

IF 1

Clinical Pediatric Endocrinology Pub Date : 2026-04-01 Epub Date: 2025-12-22 DOI: 10.1297/cpe.2025-0084

Koichi Yoshida, Yuki Okamatsu, Hiroshi Kanda, Shuichi Yatsuga

{"title":"Growth hormone therapy in a patient with short stature due to fetal alcohol syndrome: seven-year follow-up.","authors":"Koichi Yoshida, Yuki Okamatsu, Hiroshi Kanda, Shuichi Yatsuga","doi":"10.1297/cpe.2025-0084","DOIUrl":"10.1297/cpe.2025-0084","url":null,"abstract":"Fetal alcohol syndrome (FAS) is associated with persistent growth retardation, but the long-term efficacy of GH therapy for FAS-related short stature remains unclear. A Japanese girl born at 37 wk with birth weight 2,064 g (-2.1 SD) and birth height 41.5 cm (-2.7 SD) was diagnosed with FAS based on characteristic facial features, growth failure, developmental delay, and documented maternal alcohol consumption (120 g/d during pregnancy). She scored 4434 on the FASD 4-Digit Diagnostic Code. At 3 yr of age, her height was 78 cm (-4.18 SD) with poor growth velocity. GH therapy was initiated at 0.19 mg/kg/wk, increased to 0.23 mg/kg/wk, and gradually increased to 0.43 mg/kg/wk. After 7 yr of treatment, serum IGF-1 levels increased significantly from 59 ng/mL (-2.5 SD) at baseline to 306 ng/mL (+2.0 SD) at 8 yr, but height SD scores remained around -4 SD with growth velocity fluctuating between -3 and 0 SD. No adverse effects were observed. While GH therapy appears safe in FAS patients, its efficacy for improving linear growth is limited, suggesting that growth impairment in FAS involves mechanisms beyond GH deficiency, including growth plate dysfunction and peripheral GH resistance.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"35 2","pages":"173-178"},"PeriodicalIF":1.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13038387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sibling cases of congenital hypogonadotropic hypogonadism harboring compound heterozygous KISS1R variants. 含有复合杂合KISS1R变异的先天性促性腺功能减退症的同胞病例。

IF 1

Clinical Pediatric Endocrinology Pub Date : 2026-04-01 Epub Date: 2025-11-30 DOI: 10.1297/cpe.2025-0083

Yuki Miyahara, Kenichi Yamamoto, Ayaha Hata, Takatoshi Maeyama, Tamaki Wada, Natsuko Yamazaki, Saori Kinoshita, Yuri Etani, Masanobu Kawai

引用次数: 0

Improvement in post-hemispherotomy cerebral salt-wasting syndrome following intubation: A case report. 脑半球切除术后插管后脑盐消耗综合征的改善：1例报告。

IF 1.2

Clinical Pediatric Endocrinology Pub Date : 2026-01-01 Epub Date: 2025-09-10 DOI: 10.1297/cpe.2025-0050

Reiko Saito, Marie Mitani-Konno, Osamu Saito, Yukihiro Hasegawa

{"title":"Improvement in post-hemispherotomy cerebral salt-wasting syndrome following intubation: A case report.","authors":"Reiko Saito, Marie Mitani-Konno, Osamu Saito, Yukihiro Hasegawa","doi":"10.1297/cpe.2025-0050","DOIUrl":"10.1297/cpe.2025-0050","url":null,"abstract":"Cerebral salt-wasting syndrome (CSWS) is characterized by renal sodium loss following intracranial disorders, leading to hyponatremia, reduced extracellular volume, and dehydration. The mechanisms underlying CSWS remain unclear. To date, no reports have described the coexistence of arginine vasopressin deficiency (AVPD), also known as central diabetes insipidus (cDI), and CSWS following hemispherotomy. We report a case of cDI and CSWS occurring after hemispherotomy, in which CSWS improved following intubation. A 7-month-old girl with right hemimegalencephaly and cortical dysplasia underwent hemispherotomy. On postoperative day (POD) 1, AVPD was diagnosed and treated with intravenous AVP. By POD 3, she developed CSWS, characterized by increased urinary sodium excretion, decreased serum sodium levels, dehydration, polyuria, and negative fluid balance. Notably, CSWS improved markedly after intubation on POD 5. However, within one day of extubation, CSWS recurred on POD 8. Her condition gradually improved between POD 8 and POD 14. She is currently clinically stable, with her AVPD well-controlled. Conclusion: AVPD and CSWS can co-occur after hemispherotomy, even without hypothalamic-pituitary involvement. The improvement and recurrence of CSWS associated with intubation and extubation suggest that positive end-expiratory pressure may represent a novel therapeutic strategy for CSWS.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"35 1","pages":"104-109"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12779383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical features of neonatal Graves' disease revealed by twelve cases that require- antithyroid therapy. 新生儿Graves病12例需要抗甲状腺治疗的临床特点分析。

IF 1.2

Clinical Pediatric Endocrinology Pub Date : 2026-01-01 Epub Date: 2025-10-10 DOI: 10.1297/cpe.2024-0085

Eriko Adachi, Ryosei Iemura, Yumi Tanaka, Hisae Nakatani, Ryuichi Nakagawa, Yuichi Miyakawa, Akito Sutani, Kei Takasawa, Makoto Ono, Takeru Yamauchi, Manabu Sugie, Yoshihiro Minosaki, Tomohiro Morio, Kenichi Kashimada

{"title":"Clinical features of neonatal Graves' disease revealed by twelve cases that require- antithyroid therapy.","authors":"Eriko Adachi, Ryosei Iemura, Yumi Tanaka, Hisae Nakatani, Ryuichi Nakagawa, Yuichi Miyakawa, Akito Sutani, Kei Takasawa, Makoto Ono, Takeru Yamauchi, Manabu Sugie, Yoshihiro Minosaki, Tomohiro Morio, Kenichi Kashimada","doi":"10.1297/cpe.2024-0085","DOIUrl":"10.1297/cpe.2024-0085","url":null,"abstract":"Neonatal Graves' disease (GD) is rare and serious condition with a complicated clinical course, its details of the clinical features have not been clarified. This study aimed to clarify the clinical course of neonatal GD cases requiring anti-thyroid treatment. We retrospectively analyzed records from 12 neonates (7 males) diagnosed with GD from 2012 to 2021. All neonates had maternal histories of GD, with significantly elevated TRAb levels (≥ 19 IU/L) observed during the second or third trimester of pregnancy. At birth, TRAb levels were elevated in all neonates (≥ 17.4 IU/L). Thiamazole (MMI) was given to 11 neonates, with additional potassium iodide (KI) and/or β-blockers in 10 cases; one received only KI and a β-blocker. Notably, maternal TRAb levels during late pregnancy were significantly correlated with neonatal TRAb levels at birth (R2 = 0.8454, p = 0.027), and neonatal TRAb levels at birth were significantly associated with the duration of MMI treatment (R2 = 0.750, p = 0.002). Secondary central hypothyroidism was observed in 33% of cases (4/12), with unmeasurably low TSH levels at birth (< 0.01 μIU/mL) as a significant risk factor for its development (p < 0.03). These findings suggest that maternal TRAb levels significantly influence neonatal TRAb levels at birth, and neonatal TRAb levels may predict the duration of anti-thyroidal treatment.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"35 1","pages":"57-66"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12779499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Burosumab treatment for FGF23-related hypophosphatemia in a two-year-old girl with McCune-Albright syndrome. 布鲁苏单抗治疗2岁mcune - albright综合征女孩的fgf23相关低磷血症

IF 1.2

Clinical Pediatric Endocrinology Pub Date : 2026-01-01 Epub Date: 2025-10-05 DOI: 10.1297/cpe.2025-0063

Tomoki Saito, Kana Hiromoto, Naoya Morisada, Ryosuke Sakata, Tomohiro Ishii, Tomonobu Hasegawa, Keiichi Ozono, Kayo Ozaki

{"title":"Burosumab treatment for FGF23-related hypophosphatemia in a two-year-old girl with McCune-Albright syndrome.","authors":"Tomoki Saito, Kana Hiromoto, Naoya Morisada, Ryosuke Sakata, Tomohiro Ishii, Tomonobu Hasegawa, Keiichi Ozono, Kayo Ozaki","doi":"10.1297/cpe.2025-0063","DOIUrl":"10.1297/cpe.2025-0063","url":null,"abstract":"McCune-Albright syndrome (MAS) is a rare mosaic disorder caused by a gain-of-function pathogenic GNAS variant that triggers endocrine and skeletal manifestations, including fibrous dysplasia (FD) and FGF23-related hypophosphatemia. Conventional treatments (e.g., phosphate supplementation, vitamin D analogs) have shown limited efficacy against MAS. Burosumab, a monoclonal FGF23-targeting antibody, has recently been reported as a potential treatment. We report the case of a 2-yr-old girl with MAS complicated by hyperthyroidism, gonadotropin-independent precocious puberty, excess GH, Cushing syndrome, FD, and FGF23-related hypophosphatemia. Genetic testing confirmed a pathogenic GNAS variant (p.Arg201Cys). By the age of 16 mo, she experienced > 7 fractures. Burosumab (1.0 mg/kg bi-weekly) was administered at age 2 yr and 3 mo. Her serum phosphate levels normalized, tubular maximum reabsorption of phosphate-to-glomerular filtration rate ratio improved, bone pain resolved, and she experienced no further fractures since 2 yr and 7 mo, as of age 4 yr and 6 mo. To our knowledge, our patient is the youngest MAS patient treated with burosumab and the second reported case to receive burosumab among patients with genetically confirmed MAS. Burosumab improved biochemical abnormalities related to excess FGF23 and reduced fracture occurrence in our patient, supporting its efficacy in treating FGF23-related hypophosphatemia due to MAS.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"35 1","pages":"110-116"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12779380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A pediatric case of central diabetes insipidus and hypopituitarism after COVID-19 suspected with lymphocytic hypophysitis with positive anti-rabphilin-3A antibodies. 小儿新冠肺炎合并中枢性尿囊症合并垂体功能减退1例，疑似淋巴细胞性垂体炎，抗rabphilin- 3a抗体阳性。

IF 1.2

Clinical Pediatric Endocrinology Pub Date : 2026-01-01 Epub Date: 2025-08-29 DOI: 10.1297/cpe.2025-0042

Taro Fukuta, Tatsuya Fukasawa, Haruki Mizutani, Shunsuke Kato, Takuya Ishikawa, Mai Fukushima, Naoko Iwata, Haruki Fujisawa, Atsushi Suzuki, Yoshihisa Sugimura, Takashi Hamajima

{"title":"A pediatric case of central diabetes insipidus and hypopituitarism after COVID-19 suspected with lymphocytic hypophysitis with positive anti-rabphilin-3A antibodies.","authors":"Taro Fukuta, Tatsuya Fukasawa, Haruki Mizutani, Shunsuke Kato, Takuya Ishikawa, Mai Fukushima, Naoko Iwata, Haruki Fujisawa, Atsushi Suzuki, Yoshihisa Sugimura, Takashi Hamajima","doi":"10.1297/cpe.2025-0042","DOIUrl":"10.1297/cpe.2025-0042","url":null,"abstract":"Lymphocytic hypophysitis (LYH) is a rare autoimmune disorder characterized by lymphocytic infiltration of the pituitary gland, leading to central diabetes insipidus (CDI) and hypopituitarism. Although distinguishing LYH from other diseases presenting with pituitary enlargement is challenging, the use of anti-rabphilin-3A antibody (RPH3A-Ab) in the diagnosis of LYH has been recently reported. Case reports of LYH following coronavirus disease 2019 (COVID-19) infection in adult and adolescent patients have been accumulated. Here, we present the first case confirming the presence of RPH3A-Abs in pediatric CDI following COVID-19. A 4-yr-old girl developed CDI one week after COVID-19, and anterior hypopituitarism was confirmed 14 mo later. Head magnetic resonance imaging (MRI) revealed progressive pituitary stalk thickening, which subsequently improved. Although other disease-specific markers did not increase, serological testing confirmed the presence of RPH3A-Ab, supporting the clinical diagnosis of LYH. It has previously reported that RPH3A-Ab demonstrate high sensitivity and specificity in differential diagnosis of LYH, and RPH3A-Ab are also identified as positive in pediatric cases of LYH with a biopsy. Additionally, this is the first documented prepubertal case of LYH following COVID-19. Our case study indicates that LYH can occur in children after COVID-19, and RPH3A-Ab may be useful in its diagnosis.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"35 1","pages":"98-103"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12779386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hydrocortisone dosage at 3 years of age is positively correlated with body mass index at 10 years in individuals with 21-hydroxylase deficiency. 21-羟化酶缺乏症患者3岁时氢化可的松剂量与10岁时体重指数呈正相关。

IF 1.2

Clinical Pediatric Endocrinology Pub Date : 2026-01-01 Epub Date: 2025-10-04 DOI: 10.1297/cpe.2025-0065

Yuki Miyahara, Ayaha Hata, Tamaki Wada, Takatoshi Maeyama, Satsuki Nishigaki, Shinobu Ida, Yuri Etani, Masanobu Kawai

{"title":"Hydrocortisone dosage at 3 years of age is positively correlated with body mass index at 10 years in individuals with 21-hydroxylase deficiency.","authors":"Yuki Miyahara, Ayaha Hata, Tamaki Wada, Takatoshi Maeyama, Satsuki Nishigaki, Shinobu Ida, Yuri Etani, Masanobu Kawai","doi":"10.1297/cpe.2025-0065","DOIUrl":"10.1297/cpe.2025-0065","url":null,"abstract":"Obesity is a major complication in individuals with 21-hydroxylase deficiency (21-OHD) and excessive hydrocortisone (HC) dosing is a likely contributing factor. However, the association between the HC dosage and body mass index (BMI) during childhood remains unclear. We previously reported a positive correlation between HC dosage during late infancy and a subsequent increase in BMI. In this study, we expanded our research to assess the impact of HC dosage during childhood. We retrospectively collected data on HC dosages and BMI in 28 patients with 21-OHD (9 boys and 19 girls) at both 3 and 10 yr of age and conducted correlation analyses between HC dosage and BMI. No significant cross-sectional associations were observed between the body-surface-area adjusted HC dosage (HC/BSA) and BMI standard deviation score (BMI-SDS) at either 3 or 10 yr of age. However, the HC/BSA at 3 yr positively correlated with the BMI-SDS at 10 yr, indicating a longitudinal relationship. Furthermore, children whose HC/BSA at 3 yr fell almost within the guideline-recommended range exhibited significantly lower BMI-SDS at 10 yr compared to those receiving higher doses. The longitudinal association between HC dosage and BMI suggests the importance of careful HC dose monitoring, although causality could not be established.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"35 1","pages":"50-66"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12779381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0